SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Takeda Pharmaceutical Company Limited(4%),Takeda Ventures, Inc(4%)
6-K: Earnings Report for the Three-month Period Ended June 30, 2024
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
144: Notice of proposed sale of securities pursuant to Rule 144
6-K: Corporate Governance Report
6-K: Takeda Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees
6-K: Closure of Notes Sale Pursuant
6-K: Results of the Exercise of Voting Rights of the 148th Ordinary General Meeting of Shareholders
6-K: 2024 Annual Integrated Report
424B2: Prospectus
No Data